Added to YB: 2026-07-21
Pitch date: 2026-07-17
GSK [neutral]
GSK plc
-0.84%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 76.3B
Pitch Price
GBP 19.09
Price Target
N/A
Dividend
3.76%
EV/EBITDA
7.87
P/E
13.50
EV/Sales
2.79
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 17/7/2026 - GSK – Mixed pipeline news
GSK (update): Mixed pipeline news — Jemperli phase II & Ris-Rez phase III (China SCLC) oncology wins, but camlipixant RCC failed phase III (from $2bn 2023 BELLUS buy), implying writedown/lower sales est. 57 medicines/vaccines in pipeline. Cheap at 9.6x 2027 EPS, 4.0% yield, £79bn cap.
Read full article (2 min)